Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9190 plus peginterferon alfa-2a and ribavirin versus placebo plus peginterferon alfa-2a and ribavirin in genotype 1 chronic hepatitis C
2008-004527-31Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tegobuvir in hepatitis C virus infection (3 arms), sponsored by Gilead Sciences. Primary endpoints: Complete early virologic response rate and Sustained virologic response rate. Started Sep 2008; status: completed.
02
Drugs
tegobuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2008-004527-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004527-31.